Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/PRKDC_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/PRKDC_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PRKDC_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PRKDC_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/PRKDC_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PRKDC_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/PRKDC_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PRKDC_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PRKDC_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00023202 | Skin | AK | lymphoid progenitor cell differentiation | 7/1910 | 22/18723 | 4.88e-03 | 2.77e-02 | 7 |
GO:00022535 | Skin | AK | activation of immune response | 54/1910 | 375/18723 | 5.90e-03 | 3.20e-02 | 54 |
GO:00315706 | Skin | AK | DNA integrity checkpoint | 22/1910 | 123/18723 | 6.33e-03 | 3.38e-02 | 22 |
GO:001810716 | Skin | AK | peptidyl-threonine phosphorylation | 21/1910 | 116/18723 | 6.54e-03 | 3.48e-02 | 21 |
GO:00000755 | Skin | AK | cell cycle checkpoint | 28/1910 | 169/18723 | 6.83e-03 | 3.60e-02 | 28 |
GO:00450886 | Skin | AK | regulation of innate immune response | 34/1910 | 218/18723 | 8.06e-03 | 4.06e-02 | 34 |
GO:000193325 | Skin | AK | negative regulation of protein phosphorylation | 49/1910 | 342/18723 | 9.23e-03 | 4.52e-02 | 49 |
GO:00313496 | Skin | AK | positive regulation of defense response | 41/1910 | 278/18723 | 1.02e-02 | 4.86e-02 | 41 |
GO:0097193112 | Skin | SCCIS | intrinsic apoptotic signaling pathway | 42/919 | 288/18723 | 2.40e-10 | 2.12e-07 | 42 |
GO:003210315 | Skin | SCCIS | positive regulation of response to external stimulus | 51/919 | 427/18723 | 3.99e-09 | 1.76e-06 | 51 |
GO:0042110110 | Skin | SCCIS | T cell activation | 53/919 | 487/18723 | 4.77e-08 | 8.19e-06 | 53 |
GO:000268318 | Skin | SCCIS | negative regulation of immune system process | 49/919 | 434/18723 | 4.92e-08 | 8.19e-06 | 49 |
GO:0009314110 | Skin | SCCIS | response to radiation | 50/919 | 456/18723 | 9.08e-08 | 1.27e-05 | 50 |
GO:0007568110 | Skin | SCCIS | aging | 41/919 | 339/18723 | 9.54e-08 | 1.29e-05 | 41 |
GO:0050673110 | Skin | SCCIS | epithelial cell proliferation | 48/919 | 437/18723 | 1.56e-07 | 1.84e-05 | 48 |
GO:0042255112 | Skin | SCCIS | ribosome assembly | 15/919 | 61/18723 | 1.75e-07 | 1.93e-05 | 15 |
GO:190210516 | Skin | SCCIS | regulation of leukocyte differentiation | 35/919 | 279/18723 | 3.43e-07 | 3.03e-05 | 35 |
GO:0042274112 | Skin | SCCIS | ribosomal small subunit biogenesis | 16/919 | 73/18723 | 3.77e-07 | 3.23e-05 | 16 |
GO:0022604111 | Skin | SCCIS | regulation of cell morphogenesis | 36/919 | 309/18723 | 1.41e-06 | 8.79e-05 | 36 |
GO:0048511110 | Skin | SCCIS | rhythmic process | 35/919 | 298/18723 | 1.63e-06 | 9.13e-05 | 35 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PRKDC | SNV | Missense_Mutation | | c.1855G>C | p.Asp619His | p.D619H | P78527 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
PRKDC | SNV | Missense_Mutation | novel | c.3658N>G | p.Leu1220Val | p.L1220V | P78527 | protein_coding | deleterious(0.01) | possibly_damaging(0.622) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
PRKDC | SNV | Missense_Mutation | novel | c.1504N>A | p.Glu502Lys | p.E502K | P78527 | protein_coding | tolerated(0.18) | benign(0.076) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
PRKDC | SNV | Missense_Mutation | novel | c.5396N>G | p.Glu1799Gly | p.E1799G | P78527 | protein_coding | tolerated(0.13) | benign(0.118) | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
PRKDC | SNV | Missense_Mutation | | c.9458C>G | p.Ser3153Cys | p.S3153C | P78527 | protein_coding | deleterious(0) | possibly_damaging(0.907) | TCGA-A7-A13D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
PRKDC | SNV | Missense_Mutation | novel | c.5745N>C | p.Leu1915Phe | p.L1915F | P78527 | protein_coding | deleterious(0) | probably_damaging(0.914) | TCGA-A7-A6VV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR |
PRKDC | SNV | Missense_Mutation | | c.2706A>T | p.Lys902Asn | p.K902N | P78527 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A7-A6VX-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | CR |
PRKDC | SNV | Missense_Mutation | | c.2210N>T | p.Pro737Leu | p.P737L | P78527 | protein_coding | deleterious(0.01) | benign(0.354) | TCGA-A8-A099-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | exemestane | SD |
PRKDC | SNV | Missense_Mutation | | c.6367N>T | p.Pro2123Ser | p.P2123S | P78527 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PRKDC | SNV | Missense_Mutation | | c.3394N>A | p.Asp1132Asn | p.D1132N | P78527 | protein_coding | tolerated(0.21) | benign(0.055) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5591 | PRKDC | TRANSCRIPTION FACTOR COMPLEX, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, PHOSPHATIDYLINOSITOL 3 KINASE, CLINICALLY ACTIONABLE | inhibitor | 252827496 | | |
5591 | PRKDC | TRANSCRIPTION FACTOR COMPLEX, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, PHOSPHATIDYLINOSITOL 3 KINASE, CLINICALLY ACTIONABLE | | M9831 | | |
5591 | PRKDC | TRANSCRIPTION FACTOR COMPLEX, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, PHOSPHATIDYLINOSITOL 3 KINASE, CLINICALLY ACTIONABLE | | KU-0060648 | CHEMBL1086377 | 23855836 |
5591 | PRKDC | TRANSCRIPTION FACTOR COMPLEX, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, PHOSPHATIDYLINOSITOL 3 KINASE, CLINICALLY ACTIONABLE | inhibitor | 178102582 | | |
5591 | PRKDC | TRANSCRIPTION FACTOR COMPLEX, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, PHOSPHATIDYLINOSITOL 3 KINASE, CLINICALLY ACTIONABLE | inhibitor | 249565693 | | |
5591 | PRKDC | TRANSCRIPTION FACTOR COMPLEX, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, PHOSPHATIDYLINOSITOL 3 KINASE, CLINICALLY ACTIONABLE | inhibitor | 354702239 | | |
5591 | PRKDC | TRANSCRIPTION FACTOR COMPLEX, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, PHOSPHATIDYLINOSITOL 3 KINASE, CLINICALLY ACTIONABLE | inhibitor | 178102681 | WORTMANNIN | |
5591 | PRKDC | TRANSCRIPTION FACTOR COMPLEX, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, PHOSPHATIDYLINOSITOL 3 KINASE, CLINICALLY ACTIONABLE | | SF1126 | | |
5591 | PRKDC | TRANSCRIPTION FACTOR COMPLEX, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, PHOSPHATIDYLINOSITOL 3 KINASE, CLINICALLY ACTIONABLE | inhibitor | 249565692 | | |
5591 | PRKDC | TRANSCRIPTION FACTOR COMPLEX, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, PHOSPHATIDYLINOSITOL 3 KINASE, CLINICALLY ACTIONABLE | inhibitor | 404859048 | | |